GeneThera, Inc. (GTHA.OB) Signs Contracts With Xpention Genetics, Inc. And Begins Transition From Development Company To Commercial Enterprise
10/19/2005 5:10:48 PM
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--July 19, 2005--GeneThera, Inc. (OTCBB:GTHA) is pleased to announce that with the signing of its first two contracts with Xpention Genetics, Inc. (OTCBB:XPNG), the company has started their transition from a development company to that of a revenue-generating commercial enterprise.
The Company executed two contracts on May 28, 2005, with Xpention Genetics that calls for GeneThera to provide research services to Xpention for development of a commercial cancer detection test in animals and humans.
The first contract, which runs for one year at $20,000 per month, calls for GeneThera to develop a cancer detection test for animals.
comments powered by